A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The objective is to investigate the efficacy and safety of two-weekly alternative regimen of
Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal
Cancer.